Creative Planning Buys 14,663 Shares of Boston Scientific Co. (NYSE:BSX)

Creative Planning increased its stake in Boston Scientific Co. (NYSE:BSX) by 7.7% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 204,208 shares of the medical equipment provider’s stock after purchasing an additional 14,663 shares during the period. Creative Planning’s holdings in Boston Scientific were worth $17,113,000 as of its most recent filing with the SEC.

Other hedge funds also recently modified their holdings of the company. BI Asset Management Fondsmaeglerselskab A S increased its position in shares of Boston Scientific by 225.6% in the first quarter. BI Asset Management Fondsmaeglerselskab A S now owns 105,671 shares of the medical equipment provider’s stock worth $7,237,000 after purchasing an additional 73,219 shares during the period. BDF Gestion acquired a new stake in shares of Boston Scientific in the 2nd quarter valued at approximately $3,570,000. Tlwm bought a new stake in shares of Boston Scientific during the 1st quarter valued at approximately $927,000. LRI Investments LLC acquired a new position in Boston Scientific during the 1st quarter worth approximately $139,000. Finally, Cetera Advisor Networks LLC lifted its stake in Boston Scientific by 11.8% in the 1st quarter. Cetera Advisor Networks LLC now owns 201,426 shares of the medical equipment provider’s stock valued at $13,796,000 after purchasing an additional 21,252 shares during the last quarter. Institutional investors own 89.07% of the company’s stock.

Insider Activity

In other news, CEO Michael F. Mahoney sold 162,777 shares of Boston Scientific stock in a transaction on Monday, October 7th. The shares were sold at an average price of $84.63, for a total value of $13,775,817.51. Following the completion of the sale, the chief executive officer now owns 1,572,096 shares in the company, valued at $133,046,484.48. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other Boston Scientific news, CEO Michael F. Mahoney sold 162,777 shares of the business’s stock in a transaction on Monday, October 7th. The shares were sold at an average price of $84.63, for a total transaction of $13,775,817.51. Following the completion of the sale, the chief executive officer now owns 1,572,096 shares in the company, valued at approximately $133,046,484.48. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Wendy Carruthers sold 6,983 shares of the business’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $81.70, for a total transaction of $570,511.10. Following the sale, the executive vice president now owns 37,468 shares of the company’s stock, valued at $3,061,135.60. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 316,253 shares of company stock worth $26,714,298 in the last quarter. 0.50% of the stock is owned by corporate insiders.

Boston Scientific Stock Down 0.0 %

Shares of NYSE BSX opened at $88.05 on Tuesday. The company has a market capitalization of $129.18 billion, a P/E ratio of 73.99, a price-to-earnings-growth ratio of 2.87 and a beta of 0.80. Boston Scientific Co. has a 52-week low of $49.15 and a 52-week high of $88.79. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.14 and a current ratio of 1.61. The company’s 50 day moving average price is $82.73 and its 200-day moving average price is $77.37.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, July 24th. The medical equipment provider reported $0.62 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.04. The company had revenue of $4.12 billion during the quarter, compared to analyst estimates of $4.02 billion. Boston Scientific had a net margin of 12.00% and a return on equity of 16.59%. Boston Scientific’s revenue for the quarter was up 14.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.53 EPS. Equities analysts forecast that Boston Scientific Co. will post 2.4 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. Raymond James upped their price target on shares of Boston Scientific from $91.00 to $94.00 and gave the stock a “strong-buy” rating in a report on Wednesday, September 4th. TD Cowen increased their target price on Boston Scientific from $86.00 to $100.00 and gave the company a “buy” rating in a research report on Monday. Evercore ISI boosted their price target on Boston Scientific from $82.00 to $90.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Robert W. Baird raised their price objective on shares of Boston Scientific from $90.00 to $91.00 and gave the company an “outperform” rating in a report on Thursday, July 25th. Finally, Barclays lifted their target price on shares of Boston Scientific from $78.00 to $86.00 and gave the stock an “overweight” rating in a research report on Thursday, August 22nd. Four equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $90.24.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.